Founded in 2013, AblaCor (formerly known as Automated Medical Instruments, Inc.) is an early-stage medical device company located in a suburb of Boston, MA. Our first product is the AblaCor AF Catheter Ablation System to advance pulmonary vein isolation (PVI) procedures for patients with atrial fibrillation (AFib), the most common irregular heart rhythm and a potentially deadly disorder. The AblaCor system is designed to overcome limitations of currently available ablation catheters for AFib by producing durable, continuous, transmural lesions the first time. AblaCor has a strong portfolio of patents issued and pending.
Led by Martin Sklar, Founder and CEO, the AblaCor leadership team brings diverse expertise to the management of our company. From making decisions that guide long-term strategy to day-to-day operations, our team combines valuable medical technology leadership and R&D experience that is creating a game-changing technology.
Dr. Ruskin is the Founder and Director Emeritus of the Cardiac Arrhythmia Service at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. Dr. Ruskin received his undergraduate degree from Tufts University and his medical degree from Harvard Medical School. He completed his residency in Internal Medicine at Beth Israel Hospital in Boston and his fellowship in Cardiovascular Disease at the Massachusetts General Hospital. He received his training in clinical cardiac electrophysiology at the USPHS Hospital in Staten Island, New York under the mentorship of Dr. Anthony Damato. In 1978, Dr. Ruskin founded the first cardiac arrhythmia service and clinical electrophysiology laboratory in New England and one of the first such services in the United States. As founder and director of the Massachusetts General Hospital Fellowship Training Program in Clinical Cardiac Electrophysiology, he has been responsible for the training and mentorship of more than 115 clinical and research fellows in the subspecialty of cardiac arrhythmias over the past 38 years, many of whom are in leadership positions at academic centers throughout the world. His major research interests include the mechanisms and management of atrial fibrillation, new antiarrhythmic drugs and innovative technologies for catheter ablation of atrial fibrillation, the mechanisms and prevention of ventricular arrhythmias and sudden cardiac death, risk stratification for sudden death, the role of arrhythmia control devices in the prevention of sudden cardiac death, the proarrhythmic effects of cardiac and non-cardiac drugs and cardiac safety issues in new drug and device development. He is an author of more than 450 original scientific publications, chapters, reviews, and monographs. Dr. Ruskin is the recipient of the 1997 Michel Mirowski Award for Excellence in Clinical Cardiology and Electrophysiology, the 2002 Heart Rhythm Society Pioneer in Pacing and Electrophysiology Award and the 2015 KCHRS Pioneer in Electrophysiology Award. He was named the inaugural incumbent of the Omran Alomran Endowed Chair in Cardiology at Massachusetts General Hospital in 2016.
Dr. Rosenthal is Director, Cardiac Devices and Electrophysiology at the University of Massachusetts Memorial Medical Center. He is also affiliated with Webster Medical Center. His clinical interests include drug and ablation therapies for supraventricular and ventricular arrhythmias, including atrial fibrillation and ischemic VT, cardiac devices including ICD's and pacemakers, lead explantation, device therapy for heart failure including cardiac resynchronization. Dr. Rosenthal received his medical degree from Albert Einstein College of Medicine of Yeshiva University, his training in medicine from UMass Medical Center, and his training in cardiology at the John Hopkins Hospital. He and has been in practice for 16 years.
"Ablacor’s novel approach of a circular ablator, with its controlled electrode-tissue contact, designed to generate continuous and transmural ablation lesions reliably, holds great promise and would be a major advance."